Improvement of the dermal epidermal junction in human reconstructed skin by a new c-xylopyranoside derivative.
Skin aging entails drastic changes in the extracellular dermal matrix (ECM) and dermal-epidermal junction (DEJ). These biological alterations are reflected in the clinical signs of aged skin. A new C-xylopyranoside derivative, C-beta-D-xylopyranoside-2-hydroxy-propane (C-Xyloside) has been shown to induce neo-synthesis of matrix proteins such as glycosaminoglycans and heparan sulfate proteoglycans. The aim of this study was to assess the effects of C-Xyloside on markers of the dermal epidermal junction. Basement membrane components, collagen IV, collagen VII and laminin 5 as well as sub-epidermal dermal markers, pro-collagen I and fibrillin 1 were analysed using immunohistochemistry in a reconstructed skin model, including a dermal equivalent populated with living fibroblasts. Levels of mRNA of collagen VII alpha1 and collagen IV alpha1 were evaluated in dermal fibroblasts using RT-PCR. The results showed that C-Xyloside significantly induced a higher deposition of basement membrane and DEJ proteins in the reconstructed skin model and increased collagen VII gene expression. These findings indicate that, in addition to stimulating glycosaminoglycan and heparan sulfate proteoglycan expression, C-Xyloside improves the morphogenesis of the whole DEJ, and strongly suggests beneficial effects in aged skin from restoring DEJ integrity.
Sok
Juliette
J
L'Oréal Recherche, Centre de Recherche C Zviak, 90 rue du Général Roguet, 92583 Clichy Cedex, France.
Pineau
Nathalie
N
Dalko-Csiba
Maria
M
Breton
Lionel
L
Bernerd
Françoise
F
D001485:Basement Membrane / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000378:metabolism; D024141:Collagen Type IV / Q000235:genetics / Q000378:metabolism; D024102:Collagen Type VIII / Q000235:genetics / Q000378:metabolism; D020405:Dermis / Q000187:drug effects* / Q000378:metabolism; D004817:Epidermis / Q000187:drug effects* / Q000378:metabolism; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000378:metabolism*; D000071838:Fibrillin-1; D000071837:Fibrillins; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006027:Glycosides / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism; D008840:Microfilament Proteins / Q000378:metabolism; D016133:Polymerase Chain Reaction; D012313:RNA / Q000378:metabolism; D000097794:Kalinin; D054392:Adipokines
D015415:Biomarkers; D015815:Cell Adhesion Molecules; D024042:Collagen Type I; D024141:Collagen Type IV; D024102:Collagen Type VIII; D016326:Extracellular Matrix Proteins; D000071838:Fibrillin-1; D000071837:Fibrillins; D006027:Glycosides; D008840:Microfilament Proteins; D012313:RNA; D000097794:Kalinin; C531898:C-xylopyranoside-2-hydroxypropane; C000605722:FBN1 protein, human; D054392:Adipokines; C010807:xylosides